Radiopharma

Eckert & Ziegler SE is joining forces with Bicycle Therapeutics to 𝗮𝗱𝘃𝗮𝗻𝗰𝗲 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀! 🚀✨ Bicycle’s pioneering 𝗯𝗶𝗰𝘆𝗰𝗹𝗶𝗰 𝗽𝗲𝗽𝘁𝗶𝗱𝗲 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 is unlocking 𝗻𝗲𝘄 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 for targeted radiopharmaceuticals—addressing 𝘂𝗻𝗺𝗲𝘁 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗻𝗲𝗲𝗱𝘀 with precision and innovation. By combining 𝘁𝗵𝗲𝗶𝗿 𝗰𝘂𝘁𝘁𝗶𝗻𝗴-𝗲𝗱𝗴𝗲 𝘀𝗰𝗶𝗲𝗻𝗰𝗲 with 𝗼𝘂𝗿 𝗖𝗗𝗠𝗢 𝗮𝗻𝗱 𝗶𝘀𝗼𝘁𝗼𝗽𝗲 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲, we are setting the stage for the 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 of targeted radiopharmaceutical therapies. 🎯 𝗧𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗶𝘀 𝗲𝘅𝘁𝗲𝗻𝘀𝗶𝘃𝗲 𝗰𝗼𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻, 𝘄𝗲 𝘄𝗶𝗹𝗹: • 𝗦𝘂𝗽𝗽𝗹𝘆 𝗵𝗶𝗴𝗵-𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗿𝗮𝗱𝗶𝗼𝗶𝘀𝗼𝘁𝗼𝗽𝗲𝘀 ⚛️ • 𝗣𝗿𝗼𝘃𝗶𝗱𝗲 𝗖𝗗𝗠𝗢 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 for Bicycle Therapeutics’ Bicycle® Radio Conjugates 🚲 • 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗲 𝗼𝘂𝗿 𝗚𝗠𝗣-𝗰𝗲𝗿𝘁𝗶𝗳𝗶𝗲𝗱 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝗶𝗲𝘀 in Berlin to ensure reliable 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 👩🔬 “We are delighted to enter into such a 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 𝗕𝗶𝗰𝘆𝗰𝗹𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, whose innovative science is being used to develop 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗲𝘀,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler. Mike Hannay, D.Sc., FRPharmS, Chief Product and Supply Chain Officer of Bicycle Therapeutics added: “𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿’𝘀 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗰𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 𝗮𝗻𝗱 𝗴𝗹𝗼𝗯𝗮𝗹 𝗿𝗲𝗮𝗰𝗵 make them the 𝗶𝗱𝗲𝗮𝗹 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 to manufacture BRC molecules as we plan to initiate our first radiopharmaceutical 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗻𝗲𝘅𝘁 𝘆𝗲𝗮𝗿.” For the full picture, 𝗰𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝗼𝘂𝗿 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲. Link in the comments down below 🔽 💬 𝗟𝗲𝘁’𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁! If you are exploring 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗿𝗮𝗱𝗶𝗼𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝘀𝗽𝗮𝗰𝗲, we’d love to discuss how 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗰𝗮𝗻 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝘆𝗼𝘂𝗿 𝗷𝗼𝘂𝗿𝗻𝗲𝘆. 🤝 #Radiopharmaceuticals #NuclearMedicine #RadioligandTherapy #ContributingToSavingLives  

🔹 𝗨𝗽𝗱𝗮𝘁𝗲 𝗼𝗻 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿’𝘀 𝗜𝗧 𝗜𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 🔹 Following a cyber-attack earlier this month, we are pleased to share that 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿’𝘀 𝗰𝗼𝗿𝗲 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝗮𝗿𝗲 𝗯𝗮𝗰𝗸 𝗶𝗻 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻. While some areas are still undergoing gradual restoration, our business operations continue, and we remain able to supply our customers. To ensure continuity, we temporarily converted digital processes to manual workflows, allowing us to uphold our commitment to delivering high-quality products and services. 🙏 𝗔 𝗵𝗲𝗮𝗿𝘁𝗳𝗲𝗹𝘁 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 to our dedicated colleagues — especially our IT teams — who have worked tirelessly to restore our systems. We also deeply appreciate the 𝗽𝗮𝘁𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗼𝗳 𝗼𝘂𝗿 𝗰𝘂𝘀𝘁𝗼𝗺𝗲𝗿𝘀 𝗮𝗻𝗱 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 as we finalize the last steps of recovery. Our priority remains 𝘀𝗮𝗳𝗲𝘁𝘆, 𝗶𝗻𝘁𝗲𝗴𝗿𝗶𝘁𝘆, 𝗮𝗻𝗱 𝗿𝗲𝗹𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆, and we do not anticipate significant adverse effects on our business. Should you experience any temporary delays in communication, we kindly ask for your continued understanding. Check out the comments for a 𝗹𝗶𝗻𝗸 𝘁𝗼 𝘁𝗵𝗲 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 🔽

🔒 𝗨𝗽𝗱𝗮𝘁𝗲 𝗼𝗻 𝗜𝗧 𝗦𝗲𝗰𝘂𝗿𝗶𝘁𝘆 𝗜𝗻𝗰𝗶𝗱𝗲𝗻𝘁 Eckert & Ziegler SE recently experienced a 𝗰𝘆𝗯𝗲𝗿𝗮𝘁𝘁𝗮𝗰𝗸 𝗮𝗳𝗳𝗲𝗰𝘁𝗶𝗻𝗴 𝗽𝗮𝗿𝘁𝘀 𝗼𝗳 𝗼𝘂𝗿 𝗜𝗧 𝘀𝘆𝘀𝘁𝗲𝗺𝘀. In response, we 𝗮𝗰𝘁𝗲𝗱 𝘀𝘄𝗶𝗳𝘁𝗹𝘆 𝗯𝘆 𝘁𝗲𝗺𝗽𝗼𝗿𝗮𝗿𝗶𝗹𝘆 𝘀𝗵𝘂𝘁𝘁𝗶𝗻𝗴 𝗱𝗼𝘄𝗻 𝗮𝗻𝗱 𝗱𝗶𝘀𝗰𝗼𝗻𝗻𝗲𝗰𝘁𝗶𝗻𝗴 𝗮𝗳𝗳𝗲𝗰𝘁𝗲𝗱 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 from the internet to 𝗽𝗿𝗼𝘁𝗲𝗰𝘁 𝗱𝗮𝘁𝗮 𝗶𝗻𝘁𝗲𝗴𝗿𝗶𝘁𝘆 𝗮𝗻𝗱 𝗺𝗶𝗻𝗶𝗺𝗶𝘇𝗲 𝗽𝗼𝘁𝗲𝗻𝘁𝗶𝗮𝗹 𝗶𝗺𝗽𝗮𝗰𝘁. A 𝘁𝗮𝘀𝗸 𝗳𝗼𝗿𝗰𝗲, supported by external cybersecurity and forensic experts, is working diligently to 𝗿𝗲𝘀𝘁𝗼𝗿𝗲 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗮𝗻𝗮𝗹𝘆𝘇𝗲 𝘁𝗵𝗲 𝗶𝗻𝗰𝗶𝗱𝗲𝗻𝘁. 📌 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗨𝗽𝗱𝗮𝘁𝗲𝘀: • Our 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗿𝗲𝗺𝗮𝗶𝗻𝘀 𝗹𝗮𝗿𝗴𝗲𝗹𝘆 𝘂𝗻𝗮𝗳𝗳𝗲𝗰𝘁𝗲𝗱. • 𝗡𝗼 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗮𝗱𝘃𝗲𝗿𝘀𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝘀 𝗼𝗻 𝗯𝘂𝘀𝗶𝗻𝗲𝘀𝘀 operations are expected at this time.    We are treating this matter with the 𝘂𝘁𝗺𝗼𝘀𝘁 𝘀𝗲𝗿𝗶𝗼𝘂𝘀𝗻𝗲𝘀𝘀 and are committed to learning from this incident to further strengthen our IT security. We will continue to provide updates as needed. 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗮𝗻𝗱 𝘁𝗿𝘂𝘀𝘁. Check out the comments for a 𝗹𝗶𝗻𝗸 𝘁𝗼 𝘁𝗵𝗲 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 🔽

📢 𝗜𝗧 𝗜𝗻𝗰𝗶𝗱𝗲𝗻𝘁 𝗨𝗽𝗱𝗮𝘁𝗲: 𝗣𝗿𝗼𝘃𝗶𝘀𝗶𝗼𝗻𝗮𝗹 𝗘𝗺𝗮𝗶𝗹 𝗔𝗱𝗱𝗿𝗲𝘀𝘀𝗲𝘀 𝗔𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 ✉️ We have made 𝗳𝘂𝗿𝘁𝗵𝗲𝗿 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗶𝗻 𝗮𝗱𝗱𝗿𝗲𝘀𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗼𝗻𝗴𝗼𝗶𝗻𝗴 𝗜𝗧 𝗶𝗻𝗰𝗶𝗱𝗲𝗻𝘁. While 𝗲𝗺𝗮𝗶𝗹 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗿𝗲𝗺𝗮𝗶𝗻𝘀 𝗱𝗶𝘀𝗿𝘂𝗽𝘁𝗲𝗱 across our Berlin headquarters and many European subsidiaries, we have set up provisional email addresses to ensure 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻: 📧 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗥𝗲𝗹𝗮𝘁𝗶𝗼𝗻𝘀: 𝗶𝗿@𝗲𝘇𝗮𝗴.𝗰𝗼𝗺 📧 𝗚𝗲𝗻𝗲𝗿𝗮𝗹 𝗜𝗻𝗾𝘂𝗶𝗿𝗶𝗲𝘀: 𝗺𝗲𝗱@𝗲𝘇𝗮𝗴.𝗰𝗼𝗺 📞 𝗣𝗵𝗼𝗻𝗲 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗿𝗲𝗺𝗮𝗶𝗻𝘀 𝗳𝘂𝗹𝗹𝘆 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲. We appreciate your patience and understanding as we continue working on a full resolution. Thank you for your support! For further updates, please check our website or follow us here on LinkedIn.

📢 𝗨𝗽𝗱𝗮𝘁𝗲 𝗼𝗻 𝗜𝗧 𝗜𝗻𝗰𝗶𝗱𝗲𝗻𝘁: 𝗣𝗵𝗼𝗻𝗲 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗥𝗲𝘀𝘁𝗼𝗿𝗲𝗱 👍 𝗚𝗼𝗼𝗱 𝗻𝗲𝘄𝘀! 📞 We are pleased to inform you that 𝗽𝗵𝗼𝗻𝗲 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 at Eckert & Ziegler SE 𝗶𝘀 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗮𝗴𝗮𝗶𝗻. However, our 𝗲𝗺𝗮𝗶𝗹 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 𝗿𝗲𝗺𝗮𝗶𝗻 𝘁𝗲𝗺𝗽𝗼𝗿𝗮𝗿𝗶𝗹𝘆 𝘂𝗻𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 due to the ongoing IT incident. 𝗣𝗹𝗲𝗮𝘀𝗲 𝗱𝗶𝗿𝗲𝗰𝘁 𝗮𝗻𝘆 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗶𝗻𝗾𝘂𝗶𝗿𝗶𝗲𝘀 𝘁𝗼 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿 𝗥𝗲𝗹𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗼 𝘁𝗵𝗲 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗲𝗺𝗮𝗶𝗹 𝗮𝗱𝗱𝗿𝗲𝘀𝘀 𝘂𝗻𝘁𝗶𝗹 𝗳𝘂𝗿𝘁𝗵𝗲𝗿 𝗻𝗼𝘁𝗶𝗰𝗲: 𝗶𝗿@𝗲𝘇𝗮𝗴.𝗰𝗼𝗺. We 𝗮𝗽𝗽𝗿𝗲𝗰𝗶𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝘂𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 as our team continues to work diligently on fully resolving the issue. For further updates, please check our website or follow us here on LinkedIn. Thank you for your support!

📣 𝗜𝗧 𝗜𝗻𝗰𝗶𝗱𝗲𝗻𝘁 𝗔𝗳𝗳𝗲𝗰𝘁𝗶𝗻𝗴 𝗖𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗖𝗵𝗮𝗻𝗻𝗲𝗹𝘀 🚨 Due to an 𝘂𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗜𝗧 𝗶𝗻𝗰𝗶𝗱𝗲𝗻𝘁, Eckert & Ziegler SE is currently 𝘂𝗻𝗮𝗯𝗹𝗲 𝘁𝗼 𝗿𝗲𝗰𝗲𝗶𝘃𝗲 𝗲𝗺𝗮𝗶𝗹𝘀 𝗼𝗿 𝗽𝗵𝗼𝗻𝗲 𝗰𝗮𝗹𝗹𝘀. We sincerely apologize for any inconvenience this may cause and want to assure our customers and partners that we are 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗱𝗶𝗹𝗶𝗴𝗲𝗻𝘁𝗹𝘆 𝘁𝗼 𝗿𝗲𝘀𝗼𝗹𝘃𝗲 𝘁𝗵𝗲 𝗶𝘀𝘀𝘂𝗲 as soon as possible. For updates, 𝗽𝗹𝗲𝗮𝘀𝗲 𝗰𝗵𝗲𝗰𝗸 𝗼𝘂𝗿 𝘄𝗲𝗯𝘀𝗶𝘁𝗲 𝗼𝗿 𝗳𝗼𝗹𝗹𝗼𝘄 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱𝗜𝗻 𝗽𝗮𝗴𝗲. Thank you for your patience and understanding! https://lnkd.in/eJkSJjqK

🚀 𝐄𝐜𝐤𝐞𝐫𝐭 & 𝐙𝐢𝐞𝐠𝐥𝐞𝐫 𝐚𝐭 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐟𝐫𝐨𝐧𝐭 𝐨𝐟 𝐒𝐚𝐱𝐨𝐧𝐲'𝐬 𝐫𝐚𝐝𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐲 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧! Last week, on January 16, 2025, a significant milestone was achieved: Leading players in radiopharmacy from Saxony joined forces to establish the nukliD - Radiopharmacy Cluster Dresden®. 💡 𝐖𝐡𝐲 𝐢𝐬 𝐬𝐮𝐜𝐡 𝐚𝐧 𝐧𝐞𝐭𝐰𝐨𝐫𝐤 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲? With nukliD®, the foundation is laid to advance radiopharmaceutical technologies – paving the way for better treatments and a stronger future in nuclear medicine. By fostering collaboration between research, industry, and public stakeholders, the nukliD® cluster aims to position Saxony as a global leader in radiopharmacy. Through these efforts, it seeks to ensure long-term growth and sustainability in this pioneering field. 🤝 𝐀 𝐬𝐭𝐫𝐨𝐧𝐠 𝐧𝐞𝐭𝐰𝐨𝐫𝐤 The founding members of nukliD® include renowned partners like ABX advanced biochemical compounds GmbH, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), ROTOP Pharmaka GmbH, CUP Contract Labs, TRIMT GmbH and of course Eckert & Ziegler- with its local subsidiaries ITD, delivering customized hot cell solutions around the world to manufacture radiopharmaceuticals, and GSR, that help to recycle radiopharmaceuticals to increase efficiency and reduce waste. Together, they are strengthening the region’s innovation and competitiveness. Photo Credit: Jürgen Lösel / biosaxony Management GmbH #ContributingToSavingLives #Radiopharmacy #InnovationInHealthcare #EckertZiegler #HotCells

🎉 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘂𝗹𝗮𝘁𝗶𝗼𝗻𝘀, Telix Pharmaceuticals Limited, on this fantastic milestone! 🙌 Happy to see the 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 𝗼𝗽𝗶𝗻𝗶𝗼𝗻 𝗳𝗼𝗿 𝘆𝗼𝘂𝗿 𝗺𝗮𝗿𝗸𝗲𝘁𝗶𝗻𝗴 𝗮𝘂𝘁𝗵𝗼𝗿𝗶𝘇𝗮𝘁𝗶𝗼𝗻 application for 𝗜𝗹𝗹𝘂𝗰𝗰𝗶𝘅®! As 𝗧𝗲𝗹𝗶𝘅'𝘀 𝗱𝗶𝘀𝘁𝗿𝗶𝗯𝘂𝘁𝗶𝗼𝗻 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗶𝗻 𝗚𝗲𝗿𝗺𝗮𝗻𝘆, Eckert & Ziegler SE is proud to support the mission of 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 𝗮𝗻𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 for patients. Together, we are contributing to the transformation of healthcare and the ongoing innovation in radiopharmaceuticals. 💙 Here’s to 𝗰𝗼𝗻𝘁𝗶𝗻𝘂𝗲𝗱 𝘀𝘂𝗰𝗰𝗲𝘀𝘀 𝗮𝗻𝗱 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 in delivering innovative solutions for nuclear medicine! 🚀 #Radiopharmaceuticals #NuclearMedicine #MolecularImaging #ContributingToSavingLives

📣 Actinium-225 License Agreement with our Chinese Joint Venture ✨ Today, Eckert & Ziegler has signed a 𝗹𝗶𝗰𝗲𝗻𝘀𝗲 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝘄𝗶𝘁𝗵 𝗤𝗶 𝗞𝗮𝗻𝗴 𝗠𝗲𝗱𝗶𝗰𝗮𝗹, Ltd (QKM), our 𝗷𝗼𝗶𝗻𝘁 𝘃𝗲𝗻𝘁𝘂𝗿𝗲 𝘄𝗶𝘁𝗵 𝗗𝗖 𝗣𝗵𝗮𝗿𝗺𝗮, for our 𝗽𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗰𝘆𝗰𝗹𝗼𝘁𝗿𝗼𝗻 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 𝘁𝗼 𝗽𝗿𝗼𝗱𝘂𝗰𝗲 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 (Ac-225). ⚛️ 💡 𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻? 💰 A one-time 𝗽𝗮𝘆𝗺𝗲𝗻𝘁 𝗼𝗳 𝗘𝗨𝗥 𝟭𝟬 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 𝗮𝗻𝗱 𝗼𝗻𝗴𝗼𝗶𝗻𝗴 𝗿𝗼𝘆𝗮𝗹𝘁𝗶𝗲𝘀 for Eckert & Ziegler. 🌐 Strengthening our position as a 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝘀𝘂𝗽𝗽𝗹𝗶𝗲𝗿 𝗼𝗳 𝗔𝗰-𝟮𝟮𝟱 for the global radiopharmaceutical industry. 📈 Substantial 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗶𝗻 𝗚𝗠𝗣-𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗔𝗰-𝟮𝟮𝟱 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗳𝗿𝗼𝗺 𝟮𝟬𝟮𝟱 onward. 𝗪𝗵𝘆 𝗔𝗰-𝟮𝟮𝟱 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: Ac-225 is showing 𝗶𝗺𝗺𝗲𝗻𝘀𝗲 𝗽𝗿𝗼𝗺𝗶𝘀𝗲 𝗶𝗻 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 𝗳𝗼𝗿 𝘁𝗿𝗲𝗮𝘁𝗶𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿𝘀 like prostate tumors, colorectal cancer, and leukemia. As 𝗱𝗲𝗺𝗮𝗻𝗱 𝗳𝗼𝗿 𝗔𝗰-𝟮𝟮𝟱 𝘀𝘂𝗿𝗴𝗲𝘀, this collaboration helps address the scarcity of this critical therapeutic isotope, ensuring patients benefit from its potential. 🙌 This agreement is a testament to our commitment to 𝗽𝗶𝗼𝗻𝗲𝗲𝗿𝗶𝗻𝗴 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗻𝘂𝗰𝗹𝗲𝗮𝗿 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲 for a healthier tomorrow.💙 #Actinium225 #Radiopharmaceuticals #NuclearMedicine #RadioligandTherapy #ContributingToSavingLives  

📣 𝗘𝗰𝗸𝗲𝗿𝘁 & 𝗭𝗶𝗲𝗴𝗹𝗲𝗿 𝗲𝘅𝘁𝗲𝗻𝗱𝘀 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗚𝗹𝘆𝗧𝗵𝗲𝗿𝗶𝘅 𝘁𝗼 𝗶𝗻𝗰𝗹𝘂𝗱𝗲 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 ⚛️ Today we're 𝗲𝘅𝗽𝗮𝗻𝗱𝗶𝗻𝗴 𝗼𝘂𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 𝘄𝗶𝘁𝗵 𝗚𝗹𝘆𝗧𝗵𝗲𝗿𝗶𝘅 Ltd, an Australian leader in targeted radiotherapy for solid tumors. This new 𝗴𝗹𝗼𝗯𝗮𝗹 𝘀𝘂𝗽𝗽𝗹𝘆 𝗮𝗴𝗿𝗲𝗲𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗔𝗰𝘁𝗶𝗻𝗶𝘂𝗺-𝟮𝟮𝟱 (Ac-225) expands our 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗯𝗲𝘆𝗼𝗻𝗱 𝗟𝘂𝘁𝗲𝘁𝗶𝘂𝗺-𝟭𝟳𝟳, supporting GlyTherix’s groundbreaking clinical research into alpha-emitting radiopharmaceuticals. 🎯 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: ✅ A 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗼𝗳 𝗔𝗰-𝟮𝟮𝟱 to support GlyTherix’s upcoming clinical trials ✅ Strengthened efforts to 𝗮𝗱𝗱𝗿𝗲𝘀𝘀 𝘁𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗱𝗲𝗺𝗮𝗻𝗱 for alpha-emitting isotopes ✅ 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 of innovative radiopharmaceuticals targeting aggressive cancers including prostate, pancreatic, and ovarian Eckert & Ziegler SE is dedicated to 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗶𝗻𝗴 𝘁𝗵𝗲 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗼𝗳 𝗵𝗶𝗴𝗵-𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗔𝗰-𝟮𝟮𝟱, with 𝗚𝗠𝗣 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗯𝘆 𝗺𝗶𝗱-𝟮𝟬𝟮𝟱. This effort will 𝗮𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵, 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀, and help bring new therapies to patients worldwide. 💬 As Dr. Harald Hasselmann, CEO of Eckert & Ziegler, puts it: “Increasing the availability of 𝗔𝗰-𝟮𝟮𝟱 𝗶𝘀 𝗼𝘂𝗿 𝗸𝗲𝘆 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲 as it will accelerate both progress in clinical research and commercial applications, which will ultimately result in the 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 for patients globally.” 🔗 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 – Link in the comments below! #Radiopharmaceuticals #Actinium225 #AlphaEmitters #NuclearMedicine #ContributingToSavingLives